HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LSTA
Lisata Therapeutics, Inc.
There isn't enough reported data to score LSTA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LSTA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Unavailable |
LSTA's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LSTA PE Valuation
LSTA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LSTA Forward outlook
There aren't enough analyst estimates for LSTA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
LSTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.64 | +$0.59 |
| Q1 2026 | -$1.86 | +$0.44 |
| Q4 2025 | -$1.91 | +$0.49 |
| Q3 2025 | -$2.13 | +$0.38 |
| Q2 2025 | -$2.23 | +$0.34 |
| Q1 2025 | -$2.30 | +$0.16 |
| Q4 2024 | -$2.40 | +$0.18 |
| Q3 2024 | -$2.51 | +$1.82 |
LSTA has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LSTA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
LSTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $100K | -90% |
LSTA's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -3079% | -2584 points |
| Q2 2025 | -6954% | N/A |
| Q4 2024 | -495% | N/A |
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over LSTA on cash generation, producing positive trailing cash flow while its opponent burns cash.
LSTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.6M | +$1.3M |
| Q1 2026 | -$3.1M | +$2.3M |
| Q4 2025 | -$3.2M | +$1.3M |
| Q3 2025 | -$3.3M | -$824K |
| Q2 2025 | -$4M | +$1.3M |
| Q1 2025 | -$5.4M | +$1.6M |
| Q4 2024 | -$4.5M | -$459K |
| Q3 2024 | -$2.5M | +$1.1M |
LSTA has burned cash in almost every quarter: −$12M over the past year, against −$16M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LSTA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LSTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +100K shares |
| 1 year | +5.8% | +501K shares |
| 3 years | +14% | +1.1M shares |
| 5 years | +224% | +6.3M shares |
| Available history | +1212% | +8.4M shares |
LSTA has 9M diluted shares, up 5.8% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LSTA Net Leverage
LSTA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LSTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 9.3 | Oversold |
LSTA's weekly RSI is 38 (neutral) and its Stochastic is 9 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LSTA PE vs Healthcare Sector
LSTA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LSTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.18 | 8.5% above |
| 20 week MA | $1.63 | 21% below |
| 50 week MA | $2.77 | 54% below |
| 100 week MA | $2.65 | 52% below |
| 200 week MA | $2.84 | 55% below |
LSTA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
LSTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.8 | $22.8 | -32% |
| 2021 | $22.8 | $13.7 | -40% |
| 2022 | $13.7 | $2.50 | -82% |
| 2023 | $2.50 | $2.73 | +9.2% |
| 2024 | $2.73 | $3.02 | +11% |
| 2025 | $3.02 | $1.97 | -35% |
| 2026 YTD | $1.97 | $1.28 | -35% |
LSTA has the edge over HIMS on returns for 2026, with the stronger performance.